Physician profile
Sajid Ehsan
NPI 1336709021
$1,505.61
in general payments reported to CMS, 2019-2025
18 companies · $622 in 2025
The $622 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2023: $369 · 2024: $391 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $254.32 | 2022-2024 | Farxiga, Lokelma, Andexxa |
| Novartis Pharmaceuticals Corporation | $249.94 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $214.48 | 2022-2025 | Eliquis, Camzyos |
| Ucb, INC. | $155.90 | 2025 | Bimzelx, Briviact |
| Glaxosmithkline, LLC. | $108.57 | 2025 | |
| Novo Nordisk INC | $102.44 | 2023-2024 | Rybelsus, Ozempic |
| Ceribell, INC. | $74.73 | 2023-2025 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Kestra Medical Technology Services, INC. | $61.89 | 2025 | Assure Wcd |
| Pfizer INC. | $51.87 | 2025 | |
| Gilead Sciences, INC. | $44.45 | 2022 | |
| Janssen Pharmaceuticals, INC | $41.25 | 2023-2024 | Xarelto |
| Mallinckrodt Hospital Products INC. | $31.67 | 2025 | Terlivaz |
| Amgen INC. | $22.50 | 2025 | Uplizna |
| Merck Sharp & Dohme LLC | $21.18 | 2023 | Dificid, Zerbaxa |
| Ferring Pharmaceuticals INC. | $19.68 | 2023 | Rebyota |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $18.77 | 2025 | Collagenase Santyl |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.59 | 2024 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $15.38 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajid Ehsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.